Loading...
Market
What will be the percentage change in Travere Therapeutics' stock (TVTX) by the end of 2024?
3
Resolution / Starting Odds
Up more than 10% • 25%
Up between 5% and 10% • 25%
Up less than 5% • 25%
Down • 25%
Stock price data from financial markets
Story
Travere's FILSPARI for IgAN Wins FDA Approval, Stock Up 5.7%
Sep 6, 2024, 04:39 AM
Travere Therapeutics has announced that its drug FILSPARI (sparsentan) has received full approval from the FDA for treating IgA nephropathy (IgAN). FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in patients with IgAN. Following the approval, Travere Therapeutics' stock (TVTX) saw a pre-market gain of 5.7%.
View original story
Similar markets
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Increases by less than 10% • 25%
Increases by 10% to 25% • 25%
Increases by 25% to 50% • 25%
Increases by more than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%